Hemophagocytic Lymphohistiocytosis

• PAED Methotrexate 12, Hemophagocytic Lymphohistiocytosis PID 672 V1.2 (2024-05-03)
  V1.2: Addition of Folinic Acid Rescue V1.1.: Title correction V1.0: Cato test done V0.1: Dosing according to primary literature

Hodgkin Lymphoma

• Nivolumab 240 / Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma, Part B PID 1375 V1.2 (2024-05-03)
  V1.2: Correction of antiemesis with the addition of Dexamethasone, addition of controls, revision of recommendations V1.1: Removal of corticosteroid according to Della Corte 2019 / Arbour 2018, replacement of Granisetron with Palonosetron during immunotherapy. V1.0 Cato test done Nivolumab duration and sequence according to primary literature, AVD duration according to ABVD. This protocol is preceded by 4 cycles of monotherapy with Nivolumab (PID1374)
• Nivolumab 240 / Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma PID 1970 V1.1 (2024-05-02)
  V1.1: Correction of antiemesis with the addition of Dexamethasone, addition of controls, revision of recommendations V1.0 Cato test done. V0.1: Duration Nivolumab and sequence according to primary literature, durations AVD according to ABVD.

Colon Cancer

• Irinotecan 80 / Sodium Folinate 500 / Fluorouracil 2000, Colorectal Carcinoma PID 1157 V1.1 (2024-05-03)
  V1.1: Mixed infusion created V1.0: Cato test done. V0.1: Run times and sequence according to primary literature.
• Oxaliplatin 100 / Sodium Folinate 400 / Fluorouracil 2400, Colorectal Carcinoma PID 1175 V1.1 (2024-05-03)
  V1.1: Mixed infusion created V1.0: Run times and order according to primary literature.
• Fluorouracil 2600 / Sodium Folinate 500, Colorectal Carcinoma PID 51 V1.1 (2024-05-02)
  V1.1: Mixed infusion created V1.0: Cato test done. V0.1: Created by A. Dresel, run times according to primary literature.

Head and Neck Tumors (Squamous Cell)

• Pembrolizumab 200 / Carboplatin 5 / Fluorouracil 1000, Head and Neck Tumors, first-line PID 1446 V1.1 (2024-05-03)
  V1.1: Correction of antiemesis with the addition of Dexamethasone, addition of controls, revision of recommendations V1.0: Cato test done. V0.1: Duration according to summary of product characteristics and primary literature, shortening of FU duration for reasons of practicability, removal of corticosteroid according to Della Corte 2019 / Arbour 2018 in antiemesis, replacement of Granisetron by Palonosetron during immunotherapy.

Lung Carcinoma, Small Cell

• Pembrolizumab 200 / Carboplatin 5 / Etoposide 100, Lung Carcinoma, Small Cell PID 630 V1.1 (2024-05-03)
  V1.1: Correction of antiemesis with the addition of Dexamethasone, addition of controls, revision of recommendations V1.0: Cato test done. V0.1: Order of substances according to the primary literature, durations according to the respective summary of product characteristics. Created by A. Dresel
• Durvalumab 1500 / Carboplatin 5 / Etoposide 100, Small Cell Lung Carcinoma PID 1593 V1.2 (2024-05-03)
  V1.2: Correction of antiemesis with the addition of Dexamethasone. V1.1 Spelling error in Etoposide dose note corrected V1.0: Cato test done Running times and dosing according to primary literature

Lung Carcinoma, Non-Small Cell

• Pembrolizumab 200 / Nab-Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer PID 35 V1.2 (2024-05-03)
  V1.2: Correction of antiemesis with the addition of Dexamethasone, addition of controls, revision of recommendations V1.1: Cato test done. Removal of corticosteroid according to Della Corte 2019 / Arbour 2018 during immunotherapy, replacement of Granisetron with Palonosetron. V1.0: Cato test done. V0.1: created by A.Dresel, order according to primary literature, durations according to the respective summaries of product characteristics

Breast Cancer

• Pembrolizumab 200 / Carboplatin 2 / Gemcitabine 1000, Breast Cancer PID 1933 V2.1 (2024-05-03)
  V2.1: Correction of antiemesis with the addition of Dexamethasone, addition of controls, revision of recommendations V2.0: Correction of days of Carboplatin according to primary literature Cato test done V1.0: Cato test done. V0.1: Dosing according to primary literature, durations according to the respective summaries of product characteristics.

Protocols in Revision

Bladder Cancer

• Sacituzumab Govitecan 10, Bladder Cancer PID 2000 V1.1

Hepatoblastoma

• PAED Cisplatin 80, Hepatoblastoma, neoadjuvant/adjuvant PID 1405 V1.0

Colon Cancer

• Trastuzumab Deruxtecan 6.4, Colorectal Carcinoma PID 2357 V1.1

Lung Carcinoma, Non-Small Cell

• Pembrolizumab 200 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer PID 842 V1.4

Breast Cancer

• Sacituzumab Govitecan 10, Breast Cancer PID 1780 V1.2

Multiple Myeloma

• Bortezomib 1.3 / Cyclophosphamide 900 / Dexamethasone 40, Multiple Myeloma PID 532 V1.2
• Bortezomib 1.3 / Doxorubicin 9 / Dexamethasone 40, Multiple Myeloma PID 529 V1.2
• Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Isatuximab 10, multiple myeloma, induction, IB, cycle 1 PID 41 V1.2
• Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Isatuximab 10, multiple myeloma, induction, IB, cycle 2-3 PID 42 V1.2
• Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, cycle 1-2 PID 1852 V1.1

Nasopharyngeal Carcinoma

• PAED Cisplatin 100 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part A PID 723 V1.0